Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Mesothelioma, Malignant 1Mesothelioma 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Advanced Malignant Solid Neoplasm 1

Interventions

Interviews as Topic 3Educational Status 3veliparib 2adavosertib 2Specimen Handling 2Palliative Care 2Methods 2Early Intervention, Educational 2trametinib 1spartalizumab 1siltuximab 1pembrolizumab 1pamiparib 1dinaciclib 1cabozantinib 1Temozolomide 1Pharmacogenomic Variants 1Patient Comfort 1Paclitaxel 1PT-100 dipeptide 1Nutrition Assessment 1Mindfulness-Based Stress Reduction 1Mindfulness 1Magnetic Resonance Spectroscopy 1Health Promotion 1Everolimus 1Diet Therapy 1Carboplatin 1Biopsy 1Behavior Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Malignant Solid Neoplasm × cabozantinib × Other solid neoplasm × Clear all
NCT05038839 2026-05-12

Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors

M.D. Anderson Cancer Center

Phase 1 Completed
44 enrolled
Other solid neoplasm

Advanced Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡